Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/nanopublications.trig#NP348772.RA4dMWf6l-v1xwqkdY2WIVGwG19iMv4EaL2t7OHedDx-c130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP348772.RA4dMWf6l-v1xwqkdY2WIVGwG19iMv4EaL2t7OHedDx-c130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP348772.RA4dMWf6l-v1xwqkdY2WIVGwG19iMv4EaL2t7OHedDx-c130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP348772.RA4dMWf6l-v1xwqkdY2WIVGwG19iMv4EaL2t7OHedDx-c130_provenance.
- NP348772.RA4dMWf6l-v1xwqkdY2WIVGwG19iMv4EaL2t7OHedDx-c130_assertion description "[Our results suggest that PSK may augment anti-tumour action via genes including multidrug resistance protein 3 (MRP3), lymphotactin (Lptn), transgelin (TAGLN), and Pirin, without disturbing cell-cycle progression, and may deserve a large clinical trial in cancer therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP348772.RA4dMWf6l-v1xwqkdY2WIVGwG19iMv4EaL2t7OHedDx-c130_provenance.
- NP348772.RA4dMWf6l-v1xwqkdY2WIVGwG19iMv4EaL2t7OHedDx-c130_assertion evidence source_evidence_literature NP348772.RA4dMWf6l-v1xwqkdY2WIVGwG19iMv4EaL2t7OHedDx-c130_provenance.
- NP348772.RA4dMWf6l-v1xwqkdY2WIVGwG19iMv4EaL2t7OHedDx-c130_assertion SIO_000772 15547752 NP348772.RA4dMWf6l-v1xwqkdY2WIVGwG19iMv4EaL2t7OHedDx-c130_provenance.
- NP348772.RA4dMWf6l-v1xwqkdY2WIVGwG19iMv4EaL2t7OHedDx-c130_assertion wasDerivedFrom befree-20140225 NP348772.RA4dMWf6l-v1xwqkdY2WIVGwG19iMv4EaL2t7OHedDx-c130_provenance.
- NP348772.RA4dMWf6l-v1xwqkdY2WIVGwG19iMv4EaL2t7OHedDx-c130_assertion wasGeneratedBy ECO_0000203 NP348772.RA4dMWf6l-v1xwqkdY2WIVGwG19iMv4EaL2t7OHedDx-c130_provenance.
- befree-20140225 importedOn "2014-02-25" NP348772.RA4dMWf6l-v1xwqkdY2WIVGwG19iMv4EaL2t7OHedDx-c130_provenance.